Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients

Molecular and Cellular Probes

Volumn 29, Issue 1, 2015, Pages 54-62

  Rossi, Francesca ^a   Newsome, Scott D ^a   Viscidi, Raphael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

JCV; Multiple sclerosis; Natalizumab; PML

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ARTICLE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; DIAGNOSTIC TEST; HUMAN; JC VIRUS; MOLECULAR DIAGNOSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SEROLOGY; SEROPREVALENCE; TREATMENT OUTCOME; ADULT; AGED; CHEMICALLY INDUCED; COMPLICATION; ISOLATION AND PURIFICATION; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; MOLECULAR PATHOLOGY; PROCEDURES; VIROLOGY; YOUNG ADULT;

JC POLYOMAVIRUS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; PATHOLOGY, MOLECULAR; RISK FACTORS; YOUNG ADULT;

EID: 84923574203     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2014.11.007     Document Type: Article

References (68)

1. Astrom K.E., Mancall E.L., Richardson E.P. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958, 81:93-111. [accessed 28.10.14]. http://www.ncbi.nlm.nih.gov/pubmed/13523006.
2. Selik R.M., Karon J.M., Ward J.W. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. JInfect Dis 1997, 176:632-636. [accessed 20.09.14]. http://www.ncbi.nlm.nih.gov/pubmed/9291308.
3. Christensen K.L.Y., Holman R.C., Hammett T.A., Belay E.D., Schonberger L.B. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology 2010, 35:178-184. 10.1159/000311014.
4. Brew B.J., Davies N.W.S., Cinque P., Clifford D.B., Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010, 6:667-679. 10.1038/nrneurol.2010.164.
5. Clifford D.B., De Luca A., DeLuca A., Simpson D.M., Arendt G., Giovannoni G., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446. 10.1016/S1474-4422(10)70028-4.
6. Ferenczy M.W., Marshall L.J., Nelson C.D.S., Atwood W.J., Nath A., Khalili K., et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012, 25:471-506. 10.1128/CMR.05031-11.
7. Rudick R.A., O'Connor P.W., Polman C.H., Goodman A.D., Ray S.S., Griffith N.M., et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010, 68:304-310. 10.1002/ana.22107.
8. Matos A., Duque V., Luxo C., Meliço-Silvestre A., Major E.O. Individuals infected with JC polyomavirus do not present detectable JC virus DNA in oropharyngeal fluids. JGen Virol 2012, 93:692-697. 10.1099/vir.0.036798-0.
9. Antonsson A., Green A.C., Mallitt K.-A., O'Rourke P.K., Pawlita M., Waterboer T., et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. JGen Virol 2010, 91:1849-1853. 10.1099/vir.0.020115-0.
10. Viscidi R.P., Rollison D.E., Sondak V.K., Silver B., Messina J.L., Giuliano A.R., et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 2011, 18:1737-1743. 10.1128/CVI.05175-11.
11. Viscidi R.P., Tazi L., Shah K.V. Polyomaviruses: progressive multifocal leukoencephalopathy and other diseases. Viral infect. humans epidemiol. control 2014, Springer. R.A. Kaslow, L.R. Stanberry, J.W. Le Duc (Eds.).
12. Hoepner R., Faissner S., Salmen A., Gold R., Chan A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. JCent Nerv Syst Dis 2014, 2014:41-49. [accessed 30.10.14]. http://www.la-press.com/efficacy-and-side-effects-of-natalizumab-therapy-in-patients-with-mult-article-a4177-abstract.
13. Jeffery D.R. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis 2013, 4:45-51. 10.1177/2040622312466279.
14. Biogen Idec, Biogen website,. http://www.biogenidec-international.com/tysabri.aspx?ID=4763.
15. Bellizzi A., Nardis C., Anzivino E., Rodìo D.M., Fioriti D., Mischitelli M., et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. JNeurovirol 2012, 18:1-11. 10.1007/s13365-012-0080-7.
16. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840. 10.1182/blood-2008-10-186999.
17. Isidoro L., Pires P., Rito L., Cordeiro G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep 2014, 2014. 10.1136/bcr-2013-201781.
18. Zaheer F., Berger J.R. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf 2012, 3:227-239. 10.1177/2042098612453849.
19. Kumar D., Bouldin T.W., Berger R.G. Acase of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010, 62:3191-3195. 10.1002/art.27687.
20. Ermis U., Weis J., Schulz J.B. PML in a patient treated with fumaric acid. NEngl J Med 2013, 368:1657-1658. 10.1056/NEJMc1211805.
21. van Oosten B.W., Killestein J., Barkhof F., Polman C.H., Wattjes M.P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. NEngl J Med 2013, 368:1658-1659. 10.1056/NEJMc1215357.
22. Sweetser M.T., Dawson K.T., Bozic C. Manufacturer's response to case reports of PML. NEngl J Med 2013, 368:1659-1661. 10.1056/NEJMc1300283.
23. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J.T. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338. 10.1038/nrd3003.
24. Carson K.R., Newsome S.D., Kim E.J., Wagner-Johnston N.D., von Geldern G., Moskowitz C.H., et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014, 120:2464-2471. 10.1002/cncr.28712.
25. Baldwin K.J., Hogg J.P. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013, 26:318-323. 10.1097/WCO.0b013e328360279f.
26. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEngl J Med 2012, 366:1870-1880. 10.1056/NEJMoa1107829.
27. Hunt D., Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012, 12:25-35. 10.1136/practneurol-2011-000092.
28. Tur C., Montalban X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 2014, 28:641-648. 10.1007/s40263-014-0168-0.
29. Gorelik L., Lerner M., Bixler S., Crossman M., Schlain B., Simon K., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303. 10.1002/ana.22128.
30. Lee P., Plavina T., Castro A., Berman M., Jaiswal D., Rivas S., et al. Asecond-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. JClin Virol 2013, 57:141-146. 10.1016/j.jcv.2013.02.002.
31. Plavina T., Subramanyam M., Bloomgren G., Richman S., Pace A., Lee S., et al. Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML. Ann Neurol 2014, 10.1002/ana.24286.
32. Bozic C., Richman S., Plavina T., Natarajan A., Scanlon J.V., Subramanyam M., et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011, 70:742-750. 10.1002/ana.22606.
33. Warnke C., Ramanujam R., Plavina T., Bergström T., Goelz S., Subramanyam M., et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. JNeurol Neurosurg Psychiatry 2013, 84:1199-1205. 10.1136/jnnp-2012-304332.
34. Trampe A.K., Hemmelmann C., Stroet A., Haghikia A., Hellwig K., Wiendl H., et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012, 78:1736-1742. 10.1212/WNL.0b013e3182583022.
35. Olsson T., Achiron A., Alfredsson L., Berger T., Brassat D., Chan A., et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013, 19:1533-1538. 10.1177/1352458513477925.
36. Outteryck O., Ongagna J.-C., Duhamel A., Zéphir H., Collongues N., Lacour A., et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. JNeurol 2012, 259:2293-2298. 10.1007/s00415-012-6487-5.
37. Berger J.R., Houff S.A., Gurwell J., Vega N., Miller C.S., Danaher R.J. JC virus antibody status underestimates infection rates. Ann Neurol 2013, 74:84-90. 10.1002/ana.23893.
38. Major E.O., Frohman E., Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. NEngl J Med 2013, 368:2240-2241. 10.1056/NEJMc1214233.
39. Sundqvist E., Buck D., Warnke C., Albrecht E., Gieger C., Khademi M., et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014, 10:e1004084. 10.1371/journal.ppat.1004084.
40. Subramanyam M., Belachew S., Compton T. More on JC viremia in natalizumab-treated patients with multiple sclerosis. NEngl J Med 2013, 369:1279-1280. 10.1056/NEJMc1308784#SA1.
41. Lin J., Bettin P., Lee J.K., Ho J.K., Sadiq S.A. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. JNeuroimmunol 2013, 261:123-128. 10.1016/j.jneuroim.2013.05.009.
42. Warnke C., von Geldern G., Markwerth P., Dehmel T., Hoepner R., Gold R., et al. Cerebrospinal fluid JC virus antibody Index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014, 10.1002/ana.24153.
43. Chen Y., Bord E., Tompkins T., Miller J., Tan C.S., Kinkel R.P., et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. NEngl J Med 2009, 361:1067-1074. 10.1056/NEJMoa0904267.
44. Rinaldi L., Rinaldi F., Perini P., Calabrese M., Seppi D., Grossi P., et al. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. JNeurol Neurosurg Psychiatry 2010, 81:1345-1350. 10.1136/jnnp.2009.201079.
45. Jilek S., Jaquiéry E., Hirsch H.H., Lysandropoulos A., Canales M., Guignard L., et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010, 9:264-272. 10.1016/S1474-4422(10)70006-5.
46. Laroni A., Giacomazzi C.G., Grimaldi L., Gallo P., Sormani M.P., Bertolotto A., et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. JNeuroimmune Pharmacol 2012, 7:665-672. 10.1007/s11481-012-9366-z.
47. Sadiq S.A., Puccio L.M., Brydon E.W.A. JCV detection in multiple sclerosis patients treated with natalizumab. JNeurol 2010, 257:954-958. 10.1007/s00415-009-5444-4.
48. Dominguez-Mozo M.I., Garcia-Montojo M., De Las Heras V., Garcia-Martinez A., Arias-Leal A.M., Casanova I., et al. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. JNeuroimmune Pharmacol 2013, 8:1277-1286. 10.1007/s11481-013-9496-y.
49. Ryschkewitsch C., Jensen P., Hou J., Fahle G., Fischer S., Major E.O. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. JVirol Methods 2004, 121:217-221. 10.1016/j.jviromet.2004.06.021.
50. Mancuso R., Saresella M., Hernis A., Marventano I., Ricci C., Agostini S., et al. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. JTransl Med 2012, 10:248. 10.1186/1479-5876-10-248.
51. Chalkias S., Dang X., Bord E., Stein M.C., Kinkel R.P., Sloane J.A., et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014, 75:925-934. 10.1002/ana.24148.
52. Bellizzi A., Anzivino E., Rodio D.M., Cioccolo S., Scrivo R., Morreale M., et al. Human polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J 2013, 10:298. 10.1186/1743-422X-10-298.
53. Gorelik L., Reid C., Testa M., Brickelmaier M., Bossolasco S., Pazzi A., et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. JInfect Dis 2011, 204:103-114. 10.1093/infdis/jir198.
54. Reid C.E., Li H., Sur G., Carmillo P., Bushnell S., Tizard R., et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. JInfect Dis 2011, 204:237-244. 10.1093/infdis/jir256.
55. Hendel-Chavez H., de Goër de Herve M.-G., Giannesini C., Mazet A.-A., Papeix C., Louapre C., et al. Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy. JVirol 2013, 87:6055-6059. 10.1128/JVI.00131-13.
56. Krumbholz M., Meinl I., Kümpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008, 71:1350-1354. 10.1212/01.wnl.0000327671.91357.96.
57. Skarica M., Eckstein C., Whartenby K.A., Calabresi P.A. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. JNeuroimmunol 2011, 235:70-76. 10.1016/j.jneuroim.2011.02.010.
58. Putzki N., Baranwal M.K., Tettenborn B., Limmroth V., Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 2010, 63:311-317. 10.1159/000302687.
59. Lesesve J.-F., Debouverie M., Decarvalho Bittencourt M., Béné M.-C. CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes. Bone Marrow Transpl 2011, 46:1489-1491. 10.1038/bmt.2010.328.
60. Planas R., Jelčić I., Schippling S., Martin R., Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012, 42:790-798. 10.1002/eji.201142108.
61. Frohman E.M., Douek D., Major E.O. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis-reply. JAMA Neurol 2014, 71:1192-1193. 10.1001/jamaneurol.2014.1858.
62. Frohman E.M., Monaco M.C., Remington G., Ryschkewitsch C., Jensen P.N., Johnson K., et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014, 71:596-602. 10.1001/jamaneurol.2014.63.
63. Warnke C., Smolianov V., Dehmel T., Andrée M., Hengel H., Zohren F., et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2011, 17:151-156. 10.1177/1352458510385834.
64. Marshall L.J., Ferenczy M.W., Daley E.L., Jensen P.N., Ryschkewitsch C.F., Major E.O. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. JVirol 2014, 88:5177-5183. 10.1128/JVI.03221-13.
65. Schwab N., Schneider-Hohendorf T., Posevitz V., Breuer J., Göbel K., Windhagen S., et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013, 81:865-871. 10.1212/WNL.0b013e3182a351fb.
66. Major E.O., Douek D.C. Risk factors for rare diseases can be risky to define: PML and natalizumab. Neurology 2013, 81:858-859. 10.1212/WNL.0b013e3182a352a6.
67. Sørensen P.S., Bertolotto A., Edan G., Giovannoni G., Gold R., Havrdova E., et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012, 18:143-152. 10.1177/1352458511435105.
68. Egli A., Infanti L., Dumoulin A., Buser A., Samaridis J., Stebler C., et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. JInfect Dis 2009, 199:837-846. [accessed 12.09.14]. http://www.ncbi.nlm.nih.gov/pubmed/19434930.